Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review.
about
The future of high-grade glioma: Where we are and where are we going.New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer.Drug Design for ALK-Positive NSCLC: an Integrated Pharmacophore-Based 3D QSAR and Virtual Screening Strategy.Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients.
P2860
Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review.
@en
type
label
Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review.
@en
prefLabel
Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review.
@en
P2093
P2860
P1476
Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review.
@en
P2093
Bruce D Dorsey
Eugen F Mesaros
Gregory R Ott
P2860
P304
P356
10.1517/13543776.2014.877890
P407
P577
2014-01-30T00:00:00Z